SAC Capital analyst Lam Wang Kwan is upbeat on the stock as he has kept a “buy” rating with an unchanged target price of 40 cents. Lam is impressed with its year ended Dec 2021 FY2021 results.
Analysts are positive on Hyphens Pharma International given its good set of FY2021 earnings ended December 2021, its latest Novem acquisition, as well as the company obtaining Singapore’s first HSA-registered e-pharmacy licence.
The company reported earnings of $6.8 million for FY2021, up 11.1% y-o-y. Revenue in the same period was up 4.1% y-o-y to $125.9 million, with part of the growth from Novem, a distribution business acquired in December 2021 for $16.3 million.
